Inhibitors of interleukin-1β converting enzyme

Details Inhibitors of interleukin-1β converting enzyme Inhibitors of interleukin-1β converting enzyme

2007-10-30

2007-10-30

Lukton, David (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Tripeptides, e.g., tripeptide thyroliberin , etc.

C514S018700, C514S019300, C548S100000, C562S571000

Reexamination Certificate

active

09886773

ABSTRACT:
The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

REFERENCES:
patent: 4276298 (1981-06-01), Jones et al.
patent: 4369183 (1983-01-01), Jones et al.
patent: 4499295 (1985-02-01), Mueller et al.
patent: 4551279 (1985-11-01), Mueller et al.
patent: 4584397 (1986-04-01), Mueller et al.
patent: 4968607 (1990-11-01), Dower et al.
patent: 5008245 (1991-04-01), Digenis et al.
patent: 5055451 (1991-10-01), Krantz et al.
patent: 5081228 (1992-01-01), Dower et al.
patent: 5158936 (1992-10-01), Krantz et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5374623 (1994-12-01), Zimmerman et al.
patent: 5411985 (1995-05-01), Bills et al.
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5462939 (1995-10-01), Dolle et al.
patent: 5486623 (1996-01-01), Zimmerman et al.
patent: 5498616 (1996-03-01), Mallamo et al.
patent: 5498695 (1996-03-01), Daumy et al.
patent: 5552400 (1996-09-01), Dolle et al.
patent: 5565430 (1996-10-01), Dolle et al.
patent: 5585357 (1996-12-01), Dolle et al.
patent: 5585486 (1996-12-01), Dolle et al.
patent: 5639745 (1997-06-01), Dolle et al.
patent: 5670494 (1997-09-01), Dolle et al.
patent: A-64514/94 (1994-12-01), None
patent: A-0 275 101 (1988-07-01), None
patent: A-0 410 411 (1991-01-01), None
patent: A-0 417 721 (1991-03-01), None
patent: A-0 479 489 (1992-04-01), None
patent: A-0 504 938 (1992-09-01), None
patent: A-0 519 748 (1992-12-01), None
patent: A-0 525 420 (1993-02-01), None
patent: A-0 528 487 (1993-02-01), None
patent: A-0 529 713 (1993-03-01), None
patent: A-0 533 226 (1993-03-01), None
patent: A-0 533 350 (1993-03-01), None
patent: A-0 547 699 (1993-06-01), None
patent: A-0 618 223 (1994-10-01), None
patent: A-0 623 592 (1994-11-01), None
patent: A-0 623 606 (1994-11-01), None
patent: A-0 628 550 (1994-12-01), None
patent: A-0 644 198 (1995-03-01), None
patent: WO 91/15577 (1991-10-01), None
patent: WO 93/05071 (1993-03-01), None
patent: WO 93/09135 (1993-05-01), None
patent: WO 93/14777 (1993-08-01), None
patent: WO 93/16710 (1993-09-01), None
patent: WO 93/25683 (1993-12-01), None
patent: WO 93/25685 (1993-12-01), None
patent: WO 93/25694 (1993-12-01), None
patent: WO 94/00154 (1994-01-01), None
patent: WO 94/03480 (1994-02-01), None
patent: WO 95/00160 (1995-01-01), None
patent: WO 95/05192 (1995-02-01), None
D. Alberg & S. Schreiber, “Structure-Based Design of a Cyclophilin-Calcineurin Bridging Ligand”,Science, 262, pp. 248-250 (1993).
P. Andrews, “Functional Groups, Drug-Receptor Interactions and Drug Design”,Trends Pharmacol. Sci., 7, pp. 148-151 (1986).
K. Appelt et al., “Design of Enzyme Inhibitors Using Iterative Protein Crystallographic Analysis”,J. Med. Chem., 34, pp. 1925-1934 (1991).
M. Ator, “Peptide and Non-peptide Inhibitors of Interleukin-1β Converting Enzyme”,Cambridge Healthtech Institute(Inflammatory Cytokine Antagonists Targets, Strategies, and Indication), (1994).
M.A. Ator and R.E. Dolle, “Interleukin-1β Converting Enzyme: Biology and the Chemistry of Inhibitors”Curr. Pharm. Design, 1, pp. 191-210 (1995).
E. Baker & J. Drenth, “The Thiol Proteases: Structure and Mechanism”, inBiological Macromolecules and Assemblies, 3, pp. 313-368 (F. Jurnak & A. McPherson eds., 1987).
J. Baldwin et al., “Thienothiopyran-2-sulfonamids: Novel Topically Active Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma”,J. Med. Chem., 32, pp. 2510-2513 (1989).
M. Barinaga, “Death Gives Birth to the Nervous System, But How?”,Science, 259, pp. 762-763 (1993).
P. Bartlett et al., “CAVEAT: A Program to Facilitate the Structure-derived Design of Biologically Active Molecules”,Molecular Recognition: Chemical and Biochemical Problems, 78, pp. 182-196 (1989).
P. Bender & J. Lee, “Pharmacological Modulation of Interleukin-1”,Annu. Rep. Med. Chem., 25, pp. 185-193 (1989).
R. Black et al., “Activation of Interleukin-1β by a Co-induced Protease”,FEBS Lett, 247, pp. 386-390 (1989).
H. Böhm, “The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors”,J. Comput. Aided Mol. Des., 6, pp. 61-78 (1992).
J. Breitner et al., “Inverse Association of Anti-Inflammatory Treatments and Alzheimer's Disease: Initial Results of a Co-twin Control Study”,Neurology, 44, pp. 227-232 (1994).
B. Brooks et al., “CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations”,J. Comput, Chem., 4, pp. 187-217 (1983).
A. Brünger, “Extension of Molecular Replacement: A New Search Strategy Based on Patterson Correlation Refinement”,Acta Crystallogr.A 46, pp. 46-57 (1990).
A. Brünger & A. Krukowski, “Slow-Cooling Protocols for Crystallographic Refinement by Simulated Annealing”,Acta Crystallogr.A 46, pp. 585-593 (1990).
U. Burkert & N. Allinger, “Methods for the Computation of Molecular Geometry”, inMolecular Mechanics,pp. 59-78 (1982).
M. Carson, “Ribbons 2.0”,J. App. Crystallogr., 24, pp. 958-961 (1991).
F. Casano et al., “The Structure and Complete Nucleotide Sequence of the Murine Gene Encoding Interleukin-1β Convertin Enzyme (ICE)”,Genomics, 20, pp. 474-481 (1994).
D. Cerretti et al., “Molecular Cloning of the Interleukin-1β Converting Enzyme”,Science, 256, pp. 97-100 (1992).
K. Chapman, “Synthesis of a Potent, Reversible Inhibitor of Interleukin-1β Converting Enzyme”,Bioorg. Med. Chem. Lett., 2, pp. 613-618 (1992).
N. Cohen, “Drug Design in Three Dimensions”,Advances in Drug Research, 14, pp. 41-145 (1985).
N. Cohen, “Rational Drug Design and Molecular Modeling”,Drugs of the Future, 10, pp. 311-328 (1985).
N. Cohen et al., “Molecular Modeling Software and Methods for Medicinal Chemistry”,J. Med. Chem., 33, pp. 883-894 (1990).
D. Davies & D. Segal, “Protein Crystallization: Micro Techniques Involving Vapor Diffusion”,Methods Enzymol, 22, pp. 266-269 (1971).
K. Dill, “Dominant Forces in Protein Folding”,Biochemistry, 29, pp. 7133-7155 (1990).
C. Dinarello, “Role of Interleukin-1 in Infectious Diseases”,Immunol. Rev., 127, pp. 119-146 (1992).
C. Dinarello et al., “Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome”,J. Am. Med. Assoc., 269, pp. 1829-1835 (1993).
R. Dolle et al., “Aspartyl α-((Diphenylphosphinyl)oxy)methyl Ketones as Novel Inhibitors of Interleukin-1β Converting Enzyme. Utility of the Diphenylphosphinic Acid Leaving Group for the Inhibition of Cysteine Proteases”,J. Med. Chem., 38, pp. 220-222 (1995).
R. Dolle et al., “Aspartyl α((1-Phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl Ketones as Interleukin-1β Converting Enzyme Inhibitors. Significance of the P1and P3Amido Nitrogens for Enzyme-Peptide Inhibitor Binding”,J. Med. Chem.37, pp. 3863-3865 (1994).
R. Dolle et al., “P1Aspartate-Based Peptide β-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1β-Converting Enzymeȁ

Affiliated with

Also associated with

Rating

Inhibitors of interleukin-1β converting enzyme does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of interleukin-1β converting enzyme, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of interleukin-1β converting enzyme will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3870048